ReviewBiochemistry and biophysics reports2026
The central function and specific molecular mechanisms of the TLR4 pathway underlying impaired intestinal barrier in necrotizing enterocolitis.
Review in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal necrotizing enterocolitisis a fatal gastrointestinal emergency affecting preterm infants, which is linked to destruction of intestinal barrier. The structural overexpression and negative regulation of Toll like receptor 4, a key receptor of lipopolysaccharidefrom Gram-negative bacteria in preterm intestinal epithelial cells, constitute a core hub connecting flora dysbiosis and barrier breakdown. When TLR4 neutrally binds with LPS, it signals the activation of the NF-κB-mediated inflammatory cascade through the MyD88/TRIF pathway which in turn induces apoptosis, necroptosis, and tight junction protein degradation in intestinal epithelial cells. degradation of tight junction protein of intestinal epithelial cells. The body naturally possesses protective mechanisms such as competitive receptors, intracellular negative regulatory networks, and microbial metabolites, which can be the target of drugs. Methods for the protection of the intestinal barrier by fine-tuning TLR4 signaling activity include small-molecule drugs, nano-delivery systems and nutritional interventions. Nonetheless, clinical translation remains hindered by the issues of TLR4 gene polymorphism, gestational age-dependent regulation, and immune balance maintenance. In the future, efforts should concentrate on the regulatory mechanisms of small molecule drugs and naturally occurring foodborne peptides. The goal is to combine the precision offered by genetic screening with a specific delivery system. This will allow for the targeted prevention and control of TLR4 signal systems. Ultimately, this will lead to a breakthrough in tackling the challenges associated with NEC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.